Asthma Clinical Trial
Official title:
Improving Asthma Outcomes Through Stress Management
| NCT number | NCT02374138 |
| Other study ID # | 5819 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | May 2015 |
| Est. completion date | May 2017 |
| Verified date | August 2019 |
| Source | Children's Research Institute |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Uncontrolled asthma in at-risk youth responds well to guideline-based therapy when patients
remain adherent to their management plans. Adherence to inhaled corticosteroids (ICS), when
indicated for persistent or uncontrolled asthma, is a critical component of most asthma
management plans, and other self-management practices such as trigger avoidance are similarly
related to improved asthma outcomes. Adherence to self-management practices is mediated by
multiple factors, including psychosocial stress of parents and their children.
A targeted, culturally appropriate intervention to manage psychosocial stress among the
parents of young, African American, and socioeconomically disadvantaged urban children with
asthma who are receiving guideline-based care may improve asthma self-management, and
therefore asthma outcomes.
Our overall aim is to implement and evaluate a highly collaborative, multi-dimensional,
culturally appropriate and community-based asthma intervention to augment existing
guideline-based best practice. The intervention will target the parents of at-risk, urban,
African American youth, and will employ individualized psychosocial stress management and
peer support.
| Status | Completed |
| Enrollment | 217 |
| Est. completion date | May 2017 |
| Est. primary completion date | November 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 4 Years to 12 Years |
| Eligibility |
We plan to enroll parent-child dyads that meet the following criteria: Inclusion criteria (Parent): - self-identify as African-American - both the legal guardian and primary asthma caregiver of an eligible child. Exclusion criteria (Parent): - unable or unwilling to sign informed consent document - exclusionary psychiatric condition, including but not limited to psychosis, based on the screening form at recruitment - enrolled in another asthma research study. Inclusion criteria (Child): - parent-identified as African-American - age 4-12 years inclusive at recruitment - physician diagnosis of persistent asthma - publicly financed insurance Exclusion criteria (Child): - chronic medical condition (other than asthma) including but not limited to diabetes, sickle cell disease, heart disease, lung disease or neurological disorder. In addition, the PI may choose to not include a participant if he does not believe it is in the family's best interest to participate. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Children's National Medical Center | Washington | District of Columbia |
| Lead Sponsor | Collaborator |
|---|---|
| Stephen J. Teach, MD, MPH | Patient-Centered Outcomes Research Institute |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Sociodemographics | Age, gender, race, ethnicity, insurance type, parental education, household income, family medical history | Baseline | |
| Other | Number of Participants With Positive Smoke Exposure | Participants with environmental smoke exposure. Responses were regrouped as negative (none) or positive (daily, often, or rarely) based on two questions: "How often did anyone smoke inside the home where child usually lives?" or "How often did anyone smoke in the room where child usually sleeps?" A positive response on either or both questions was considered positive exposure. | Repeated Measures at 6 and 12 months (3m data collected for repeated measures) | |
| Other | Parental Health Literacy | Single Item Literacy Screener (SILS) | Baseline | |
| Other | Use of Existing Ancillary Services | Assessed at 6m and 12m following enrollment | ||
| Other | Parental Resilience | Parental resilience assessed by score on Revised Life Orientation Test (LOT-R) measure. The LOT-R assesses optimism/resilience, and is comprised of 10 questions. Scores range from 0-40, with a higher score indicating a higher level of optimism. | Baseline | |
| Other | Intervention Component Uptake | Completion of intervention sessions | 6 month intervention period | |
| Other | Intervention Satisfaction | Brief survey of satisfaction with intervention components. | 6 month intervention period | |
| Other | Intervention Fidelity | Checklist of staff's fidelity to individual components of intervention protocol | 6 month intervention period | |
| Primary | Symptom-free Days in the Last 14 Days | Symptom-free days are defined as a 24-hour period with no coughing, wheezing, chest tightness, or shortness of breath and no need for rescue medications | Repeated Measures at 6 months (3 month data collected to allow for repeated measures) | |
| Secondary | Asthma Morbidity - Nighttime Asthma Symptoms | Nights of asthma symptoms in prior 14d | Repeated Measures at 6 and 12 months (3m data collected for repeated measures) | |
| Secondary | Asthma Severity and Control | Repeated Measures at 3, 6, and 12 months | ||
| Secondary | Asthma Medication Adherence | Reported use of inhaled corticosteroids and LTRA in past two days | Repeated Measures at 6 and 12 months (3m data collected for repeated measures) | |
| Secondary | Health Care Utilization - Emergency Department Visits for Asthma | Health care utilization - emergency department visits for asthma over six month and twelve month follow up periods. Reported as those documented in the electronic medical record of Children's National Health System plus parent report of visits elsewhere | 12 months after enrollment | |
| Secondary | Asthma Exacerbations - Courses of Systemic Steroids | Courses of systemic steroids over 12m follow up period | Assessed at 6m and 12m following enrollment | |
| Secondary | Parental Stress | Score on Perceived Stress Scale (PSS). The Perceived Stress Scale consists of 10 questions and is a measure of the degree to which situations in one's life are appraised as stressful. Scores range from 0 - 40, with higher scores indicating a higher level of perceived stress. | Repeated Measures at 6 and 12 months (3m data collected for repeated measures) | |
| Secondary | Parental Depression | Score on Center for Epidemiologic Studies Depression Scale (CES-D - 10). The CESD-10 scale screens for depressive symptoms. Scores range from 0-30, with higher scores indicating a higher degree of depressive symptoms. | Repeated Measures at 6 and 12 months (3m data collected for repeated measures) | |
| Secondary | Child Anxiety | PROMIS Parent Proxy Anxiety. For PROMIS instruments, T-scores rescale the raw score into a standardized score with a mean of 50 and a standard deviation of 10. A higher T-score represents higher anxiety and/or depression. | Repeated Measures at 6 and 12 months (3m data collected for repeated measures) | |
| Secondary | Child Depression | PROMIS Parent Proxy Depressive Symptoms is a parent-report assessment of child depression. For PROMIS instruments, T-scores rescale the raw score into a standardized score with a mean of 50 and a standard deviation of 10. A higher T-score represents higher anxiety and/or depression. | Repeated Measures at 6 and 12 months (3m data collected for repeated measures) | |
| Secondary | Caregiver Quality of Life | Caregiver quality of life score, assessed by modified Pediatric Asthma Caregiver Quality of Life Questionnaire (PACQLQ). The measure had five response options, with scores ranging from 13-65 and higher scores meaning better quality of life. No subscales were analyzed. | Repeated Measures at 6 and 12 months (3m data collected for repeated measures) | |
| Secondary | Number of Participants With AEs and SAEs | Safety data: Number of Participants with AEs and SAEs | 12m follow up period | |
| Secondary | Economic Outcomes | Analysis of costs of care in both groups | 12m follow-up period | |
| Secondary | Caregiver Smoking Behavior | parent report of cigarettes smoked per day | Repeated Measures at 6 and 12 months | |
| Secondary | Coping Strategies | Brief COPE | Repeated measures at 12m FU (6m data used for repeated measures) | |
| Secondary | Mindfulness | Interpersonal Mindfulness in Parenting | Repeated Measures at 6 and 12 months | |
| Secondary | Parental Resilience | Parental resilience assessed by score on Revised Life Orientation Test (LOT-R) measure. The LOT-R assesses optimism/resilience, and is comprised of 10 questions. Scores range from 0-40, with a higher score indicating a higher level of optimism. | Repeated Measures at 6 and 12 months | |
| Secondary | Exacerbations - Hospital Admissions | Number of participants with hospital admissions due to exacerbations | Assessed at 6m and 12m after enrollment | |
| Secondary | Symptom-free Days in the Last 14 Days | Symptom-free days are defined as a 24-hour period with no coughing, wheezing, chest tightness, or shortness of breath and no need for rescue medications | Repeated Measures at 12 months (with data also assessed at 3m and 6m) | |
| Secondary | Asthma Morbidity - Daytime Asthma Symptoms, Days of Activity Limitations, and Days of Quick Relief Medicine Use | Days of asthma symptoms, activity limitation, and quick relief medicine use in prior 14d | Repeated measures at 6 and 12 months (3m data collected for repeated measures) |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|